The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Next Generation Antibody Drug Market Through 2030?
The next generation antibody drug market has experienced swift growth recently. It is forecast to expand from $16.4 billion in 2025 to $18.93 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.4%. This past growth can be attributed to the achievements of monoclonal antibody therapies, an increasing prevalence of cancer, progress in antibody engineering, elevated investment in biologics research and development, and regulatory approvals for antibody drugs.
The next generation antibody drug market is projected to experience substantial expansion in the coming years. This market is set to reach a valuation of $33.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.4%. This projected growth is driven by several factors, including the increasing adoption of precision medicine, a rising demand for targeted biologics, progress in conjugation technologies, the widening scope of treatments for autoimmune diseases, and the growing number of oncology drug candidates in development. Key trends anticipated during this period encompass the swift progress in developing bispecific antibodies, the broader embrace of antibody-drug conjugates, an intensifying focus on precision-targeted therapies, the expansion of antibody uses beyond cancer treatment, and an increase in clinical trials for sophisticated antibody platforms.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24335&type=smp
What Influential Factors Are Boosting The Next Generation Antibody Drug Market Demand?
The growing emphasis on personalized medicine is projected to stimulate the expansion of the next-generation antibody-drug market moving forward. Personalized medicine refers to a medical methodology that customizes treatment and healthcare strategies for individual patients based on their genetic, environmental, and lifestyle factors, thus ensuring more potent and specific therapies. The rise of personalized medicine is attributed to advancements in genomic sequencing, which facilitate more accurate diagnoses and targeted treatment strategies. Next-generation antibody drugs bolster the focus on personalized medicine by enabling the development of targeted therapies tailored to individual patients’ genetic profiles and disease characteristics, thereby improving efficacy and minimizing adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based organization promoting the adoption of personalized medicine, the United States Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Therefore, the increasing focus on personalized medicine acts as a driver for the next-generation antibody drug market.
How Are Different Segment Groups Identified Within The Next Generation Antibody Drug Market?
The next generation antibody drug market covered in this report is segmented –
1) By Product Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Mechanism Of Action: Checkpoint Inhibitors, Immune Modulators, Receptor Blockers, Targeted Cytotoxic Agents, Neutralizing Antibodies
3) By Delivery Method: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration
4) By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Other Applications
5) By End User: Hospitals, Research Institutes, Specialty Clinics, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Human Monoclonal Antibodies, Murine Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies
2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics, Bispecific Antibodies For Cytokine Modulation, Bispecific Antibodies With Extended Half-Life Technologies
3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates, Non-Cleavable Linker Antibody-Drug Conjugates, Site-Specific Conjugated Antibody-Drug Conjugates
Which Trends Are Contributing To Changes In The Next Generation Antibody Drug Market?
Key players within the next generation antibody drug market are focusing on developing innovative solutions, such as antibody-drug conjugates, to enhance targeted cancer therapies, improve therapeutic effectiveness, and reduce overall systemic toxicity. An antibody-drug conjugate (ADC) functions as a specific cancer therapy that combines a monoclonal antibody with a cytotoxic drug via a linker, enabling the selective delivery of the drug to tumor cells while minimizing damage to healthy tissue. For example, in January 2024, BioNTech SE, a Germany-based biotechnology firm, partnered with Duality Biologics (Suzhou) Co. Ltd., a China-based pharmaceutical company, and secured a Fast Track designation from the U.S. Food and Drug Administration (FDA) for their advanced antibody-drug conjugate (ADC) candidate, BNT325/DB-1305, intended for treating platinum-resistant ovarian cancer. This drug employs DualityBio’s innovative DITAC (Duality Immune Toxin Antibody Conjugates) platform, which integrates a highly potent cytotoxic payload with a monoclonal antibody, ensuring precise delivery of treatment directly to cancer cells. The ability of BNT325/DB-1305 to accurately target cancer cells while limiting harm to healthy tissues represents a significant benefit in boosting treatment efficacy and reducing side effects.
Who Are The Firms Contributing To The Next Generation Antibody Drug Market Ecosystem?
Major companies operating in the next generation antibody drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited, Actinium Pharmaceuticals Inc.
Access The Complete Next Generation Antibody Drug Market Report:
https://www.thebusinessresearchcompany.com/report/next-generation-antibody-drug-global-market-report
Which Region Is The Primary Market For The Next Generation Antibody Drug Market?
North America was the largest region in the next generation antibody drug market in 2025. The regions covered in the next generation antibody drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Next Generation Antibody Drug Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24335&type=smp
Browse Through More Reports Similar to the Global Next Generation Antibody Drug Market 2026, By The Business Research Company
Next Generation Antibody Therapeutics Market Report 2026
Antibody Drug Conjugates Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
Antibody Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model